Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
IPO Year: 2021
Exchange: AMEX
Website: brooklynitx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $9.00 | Overweight | Cantor Fitzgerald |
| 10/6/2021 | $20.00 | Buy | Maxim Group |
Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of Susan McClatchey as Vice President, Head of Quality. "We are aggressively preparing to handle what we believe will be a rapid ramp-up of drug development activities through our gene editing/cell therapy platform, which will require specialized resources including quality assurance," commented Howard J. Federoff, M.D., Ph.D, Brooklyn's President and Chief Executive Offi
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. "Roger's extensive R&D experience, including many years in late-stage clinical development involving a wide array of treatment modalities for hematologic malignancies and solid tumors, brings him to Brooklyn at an inflection point where his insight and understanding will help guide us to the
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021. "Jay has a long and impressive history managing the finances of multiple health systems and hospitals and leading the financial transformation of complex organizations through prudent management and strategic activities, including fundraising, business development and facilities management. We are tru
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D’Amour, Ph.D. as its Chief Scientific Officer. Dr. D’Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been wide
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Michael Andreeff, M.D., Ph.D. to Brooklyn's Scientific Advisory Board, effective May 21, 2021. Dr. Andreeff currently serves as a Professor of Medicine at MD Anderson Cancer Center where he holds the Paul and Mary Haas Chair in Genetics and is the Chief of Molecular Hematology and Therapy. Dr. Andreeff received his M.D. and Ph.D. from the University of Heidelberg, Germany, and additional training at Memorial Sloan Kettering Cancer Cent
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced the appointment of Erich Mohr, Ph.D., ICD.D. to Brooklyn's Board of Directors, effective May 7, 2021. "Dr. Erich Mohr's distinguished career as a leader of life sciences companies, as well as in academic research, will serve as an important resource to Brooklyn," said Howard J. Federoff, M.D., Ph.D. Brooklyn ImmunoTherapeutics' Chief Executive Officer and President. "Dr. Mohr has a proven track record of creating value both as a Board
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company's Scientific Advisory Board, effective April 26, 2021. Dr. During is a Harvard, MIT and Yale trained neuroscientist. He has served for 9 years as a member of the faculty of Yale as Professor of Neurosurgery, and as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities. Dr. During was a pioneer in the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a
4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
SCHEDULE 13D/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
SC TO-I - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
DEFA14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-CSR - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the final results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"), which expired on July 8, 2025. The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made approximately five business days after the pricing date (anticipated to be July 16, 2025). The final results of the Tender Offer are provided in the table below: Fund Name Ticker
BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the expiration and preliminary results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"). The Tender Offer commenced on June 9, 2025 and expired at 11:59 p.m. Eastern time on July 8, 2025. Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below. Fund Name Ticker CUSIP Shares Offered for Repurchase Shares Tendered (Preliminary Results) BlackRock Technology and Private Equity Term Trust BTX 09260Q108 106,669,074 96,627,850
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
BlackRock Technology and Private Equity Term Trust (NYSE:BTX) (the "Fund") announced today the commencement, expiration and pricing dates of the previously announced offer to repurchase up to 50% of outstanding common shares at a price per share equal to 99.5% of the Fund's net asset value ("NAV") per common share as determined on the pricing date (the "Tender Offer"). The Fund's Board of Trustees approved the dates as detailed in the table below: Commencement Date Monday, June 9, 2025 Expiration Date and Time Tuesday, July 8, 2025 at 11:59 p.m. Eastern Time, unless otherwise extended Pricing Date Wednesday July 9, 2025 Shares of the Fund w
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025 Ex-Date- 6/13/2025 Record- 6/13/2025 Payable- 7/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
BlackRock Advisors, LLC announced today the results of the Special Shareholder Meeting of the BlackRock Technology and Private Equity Term Trust (NYSE:BTX) (the "Trust"). Shareholders have approved (i) an amendment to the Trust's fundamental investment restriction with respect to industry concentration to allow the Trust to concentrate its investments in companies operating in one or more industries within the technology group of industries and (ii) a change in the Trust's diversification status under the Investment Company Act of 1940 from diversified to non-diversified. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025 Ex-Date- 6/13/2025 Record- 6/13/2025 Payable- 7/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 3/3/2025 Ex-Date- 3/14/2025 Record- 3/14/2025 Payable- 4/1/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital